HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The safety of anidulafungin.

Abstract
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.
AuthorsJosé A Vazquez
JournalExpert opinion on drug safety (Expert Opin Drug Saf) Vol. 5 Issue 6 Pg. 751-8 (Nov 2006) ISSN: 1744-764X [Electronic] England
PMID17044802 (Publication Type: Journal Article, Review)
Chemical References
  • Antifungal Agents
  • Echinocandins
  • Peptides, Cyclic
  • Anidulafungin
Topics
  • Anidulafungin
  • Animals
  • Antifungal Agents (adverse effects, blood)
  • Echinocandins
  • Humans
  • Peptides, Cyclic (adverse effects, blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: